<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03696758</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0796</org_study_id>
    <secondary_id>1UL1TR002373-01</secondary_id>
    <secondary_id>A534285</secondary_id>
    <secondary_id>SMPH/MEDICINE/PULMON MED</secondary_id>
    <secondary_id>Protocol Version 8/30/2018</secondary_id>
    <nct_id>NCT03696758</nct_id>
  </id_info>
  <brief_title>Improving Right Ventricular Function in Young Adults Born Preterm</brief_title>
  <official_title>Improving Right Ventricular Function in Young Adults Born Preterm: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to evaluate the short-term effects of sildenafil and&#xD;
      metoprolol on heart function in young adults born premature.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the short-term therapeutic effects of sildenafil and&#xD;
      metoprolol on right ventricular function in young adults born premature using novel&#xD;
      4-Dimensional flow Cardiac Magnetic Resonance Imaging.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2018</start_date>
  <completion_date type="Actual">February 24, 2020</completion_date>
  <primary_completion_date type="Actual">February 24, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Right Ventricular Energetic Efficiency Pre and Post Metoprolol</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>To characterize energy efficiency, the total Kinetic Energy across the cardiac cycle is normalized to right ventricular end-diastolic volume and left ventricular end-diastolic volume, respectively. Analysis will be completed in blinded fashion. Two imaging scans will be done - one pre and one post Metoprolol intervention. Total time from Pre-intervention scan till post intervention scan may take up to 2 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Right Ventricular Energetic Efficiency Pre and Post Sildenafil</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>To characterize energy efficiency, the total Kinetic Energy across the cardiac cycle is normalized to right ventricular end-diastolic volume and left ventricular end-diastolic volume, respectively. Analysis will be completed in blinded fashion. Two imaging scans will be done - one pre and one post Sildenafil intervention. Total time from Pre-intervention scan till post intervention scan may take up to 2 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Energetic Efficiency Pre and Post Metoprolol</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Kinetic energy (from 4D flow) normalized to ventricular volume (from MRI). Participants will receive intravenous metoprolol in between scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Ventricular Ejection Fraction Pre and Post Metoprolol</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Participants will receive intravenous metoprolol in between scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Ventricular Stroke Volume Pre and Post Metoprolol</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Participants will receive intravenous metoprolol in between scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Ventricular Systolic Volume Pre and Post Metoprolol</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Participants will receive intravenous metoprolol in between scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Ventricular Diastolic Volume Pre and Post Metoprolol</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Participants will receive intravenous metoprolol in between scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction Pre and Post Metoprolol</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Participants will receive intravenous metoprolol in between scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Stroke Volume Pre and Post Metoprolol</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Participants will receive intravenous metoprolol in between scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Systolic Volume Pre and Post Metoprolol</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Participants will receive intravenous metoprolol in between scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Diastolic Volume Pre and Post Metoprolol</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Participants will receive intravenous metoprolol in between scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Energetic Efficiency Pre and Post Sildenafil</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Kinetic energy (from 4D flow) normalized to ventricular volume (from MRI). Participants will be given sildenafil in between imaging scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Ventricular Ejection Fraction Pre and Post Sildenafil</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Participants will be given sildenafil in between imaging scans. The term &quot;ejection fraction&quot; refers to the percentage of blood that's pumped out of a filled ventricle with each heartbeat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Ventricular Stroke Volume Pre and Post Sildenafil</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Participants will be given sildenafil in between imaging scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Ventricular Systolic Volume Pre and Post Sildenafil</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Participants will be given sildenafil in between imaging scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Ventricular Diastolic Volume Pre and Post Sildenafil</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Participants will be given sildenafil in between imaging scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction Pre and Post Sildenafil</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Participants will be given sildenafil in between imaging scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Stroke Volume Pre and Post Sildenafil</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Participants will be given sildenafil in between imaging scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Systolic Volume Pre and Post Sildenafil</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Participants will be given sildenafil in between imaging scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Diastolic Volume Pre and Post Sildenafil</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Participants will be given sildenafil in between imaging scans.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Infant,Premature</condition>
  <arm_group>
    <arm_group_label>Sildenafil followed by Metoprolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol followed by Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given metoprolol in between imaging scans at one visit, and will receive intravenous sildenafil in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary Function Testing</intervention_name>
    <description>Subjects will undergo spirometry, Plethysmography, and diffusion capacity.</description>
    <arm_group_label>Metoprolol followed by Sildenafil</arm_group_label>
    <arm_group_label>Sildenafil followed by Metoprolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electrocardiogram</intervention_name>
    <description>Subjects will undergo an electrocardiogram to ensure sinus rhythm</description>
    <arm_group_label>Metoprolol followed by Sildenafil</arm_group_label>
    <arm_group_label>Sildenafil followed by Metoprolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac Magnetic Resonance Imaging</intervention_name>
    <description>Subjects will undergo positron magnetic resonance imaging to detect images of the heart</description>
    <arm_group_label>Metoprolol followed by Sildenafil</arm_group_label>
    <arm_group_label>Sildenafil followed by Metoprolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>Subjects will receive intravenous metoprolol. Dose titrated 1-5 mg every 2 minutes to achieve goal heart rate of 55-65 beats per minute, or for subjects with a resting heart rate already at goal, titrated to achieve a 10-15% reduction in heart rate.</description>
    <arm_group_label>Metoprolol followed by Sildenafil</arm_group_label>
    <arm_group_label>Sildenafil followed by Metoprolol</arm_group_label>
    <other_name>Lopressor</other_name>
    <other_name>Metolar XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
    <arm_group_label>Metoprolol followed by Sildenafil</arm_group_label>
    <arm_group_label>Sildenafil followed by Metoprolol</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Male or female aged 18-35&#xD;
&#xD;
          3. History of preterm birth (either a or b):&#xD;
&#xD;
               1. Participant in the Newborn Lung Project (birth year 1988-1991, birth weight &lt;1500&#xD;
                  g)&#xD;
&#xD;
               2. Non-NLP participant, with birth weight &lt;1500 g and gestational age 32 weeks or&#xD;
                  less, verified by medical records&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating&#xD;
&#xD;
          2. Use of prescribed medications that would interfere with study medications&#xD;
&#xD;
               1. Sildenafil: Use of phosphodiesterase type 5 inhibitors (sildenafil, tadalafil,&#xD;
                  vardenafil), nitrates, soluble guanylate cyclase inhibitor (riociguat) within 48&#xD;
                  hours of study visit&#xD;
&#xD;
               2. Metoprolol: Use of nodal blocking agents including beta blockers,&#xD;
                  non-dihydropyridine calcium channel blockers (i.e. diltiazem), and&#xD;
                  anti-arrhythmics (i.e. amiodarone)&#xD;
&#xD;
          3. Presence of known comorbidities for which these therapeutic interventions would be&#xD;
             contraindicated:&#xD;
&#xD;
               1. Moderate to severe heart failure&#xD;
&#xD;
               2. Severe bradycardia (heart rate &lt;45), or second or third-degree heart block&#xD;
&#xD;
               3. Systolic blood pressure &lt;90 mmHg or &gt;190 mmHg&#xD;
&#xD;
               4. Angina&#xD;
&#xD;
               5. Severe peripheral arterial circulatory disorders&#xD;
&#xD;
               6. History of severe bronchospasm&#xD;
&#xD;
          4. Presence of any implanted device incompatible with CMR imaging&#xD;
&#xD;
          5. Known allergic or hypersensitivity reaction to components of the study medications&#xD;
&#xD;
          6. Any other reason for which the investigator deems a subject unsafe or inappropriate&#xD;
             for study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kara N Goss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin-Madison School of Medicine and Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin-Madison School of Medicine and Public Health</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <results_first_submitted>January 14, 2021</results_first_submitted>
  <results_first_submitted_qc>February 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 25, 2021</results_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>premature adults</keyword>
  <keyword>premature</keyword>
  <keyword>premature cardiac function</keyword>
  <keyword>MRI</keyword>
  <keyword>sildenafil</keyword>
  <keyword>metoprolol</keyword>
  <keyword>CMR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT03696758/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Due to COVID shut down, 1 participant was excluded from the study before assignment to groups</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sildenafil Followed by Metoprolol</title>
          <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.</description>
        </group>
        <group group_id="P2">
          <title>Metoprolol Followed by Sildenafil</title>
          <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given metoprolol in between imaging scans at one visit, and will receive intravenous sildenafil in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Wash Out&gt;12 Hours</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Young Adults Born Premature</title>
          <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart Metoprolol: Subjects will receive intravenous metoprolol Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.8" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age (Neonatal Characteristics)</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birth weight (Neonatal Characteristics)</title>
          <units>gram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1116" spread="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Right Ventricular Energetic Efficiency Pre and Post Metoprolol</title>
        <description>To characterize energy efficiency, the total Kinetic Energy across the cardiac cycle is normalized to right ventricular end-diastolic volume and left ventricular end-diastolic volume, respectively. Analysis will be completed in blinded fashion. Two imaging scans will be done - one pre and one post Metoprolol intervention. Total time from Pre-intervention scan till post intervention scan may take up to 2 hours.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart Metoprolol: Subjects will receive intravenous metoprolol Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricular Energetic Efficiency Pre and Post Metoprolol</title>
          <description>To characterize energy efficiency, the total Kinetic Energy across the cardiac cycle is normalized to right ventricular end-diastolic volume and left ventricular end-diastolic volume, respectively. Analysis will be completed in blinded fashion. Two imaging scans will be done - one pre and one post Metoprolol intervention. Total time from Pre-intervention scan till post intervention scan may take up to 2 hours.</description>
          <units>µJ/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.004</p_value>
            <p_value_desc>p value is 0.004 for 'Pre-Metoprolol' vs 'post-Metoprolol' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Right Ventricular Energetic Efficiency Pre and Post Sildenafil</title>
        <description>To characterize energy efficiency, the total Kinetic Energy across the cardiac cycle is normalized to right ventricular end-diastolic volume and left ventricular end-diastolic volume, respectively. Analysis will be completed in blinded fashion. Two imaging scans will be done - one pre and one post Sildenafil intervention. Total time from Pre-intervention scan till post intervention scan may take up to 2 hours.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart Metoprolol: Subjects will receive intravenous metoprolol Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricular Energetic Efficiency Pre and Post Sildenafil</title>
          <description>To characterize energy efficiency, the total Kinetic Energy across the cardiac cycle is normalized to right ventricular end-diastolic volume and left ventricular end-diastolic volume, respectively. Analysis will be completed in blinded fashion. Two imaging scans will be done - one pre and one post Sildenafil intervention. Total time from Pre-intervention scan till post intervention scan may take up to 2 hours.</description>
          <units>µJ/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.13</p_value>
            <p_value_desc>P-Value is 0.13 for 'Pre-Sildenafil' vs 'Post-Sildenafil' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Energetic Efficiency Pre and Post Metoprolol</title>
        <description>Kinetic energy (from 4D flow) normalized to ventricular volume (from MRI). Participants will receive intravenous metoprolol in between scans.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Energetic Efficiency Pre and Post Metoprolol</title>
          <description>Kinetic energy (from 4D flow) normalized to ventricular volume (from MRI). Participants will receive intravenous metoprolol in between scans.</description>
          <units>µJ/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>descriptive statistics</non_inferiority_desc>
            <p_value>0.004</p_value>
            <p_value_desc>p value is 0.004 for 'Pre-Metoprolol' vs 'post-Metoprolol' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Right Ventricular Ejection Fraction Pre and Post Metoprolol</title>
        <description>Participants will receive intravenous metoprolol in between scans.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricular Ejection Fraction Pre and Post Metoprolol</title>
          <description>Participants will receive intravenous metoprolol in between scans.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.1</p_value>
            <p_value_desc>p value is 0.10 for 'Pre-Metoprolol' vs 'post-Metoprolol' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Right Ventricular Stroke Volume Pre and Post Metoprolol</title>
        <description>Participants will receive intravenous metoprolol in between scans.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricular Stroke Volume Pre and Post Metoprolol</title>
          <description>Participants will receive intravenous metoprolol in between scans.</description>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.09</p_value>
            <p_value_desc>p value is 0.09 for 'Pre-Metoprolol' vs 'post-Metoprolol' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Right Ventricular Systolic Volume Pre and Post Metoprolol</title>
        <description>Participants will receive intravenous metoprolol in between scans.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricular Systolic Volume Pre and Post Metoprolol</title>
          <description>Participants will receive intravenous metoprolol in between scans.</description>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.10</p_value>
            <p_value_desc>p value is 0.10 for 'Pre-Metoprolol' vs 'post-Metoprolol' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Right Ventricular Diastolic Volume Pre and Post Metoprolol</title>
        <description>Participants will receive intravenous metoprolol in between scans.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricular Diastolic Volume Pre and Post Metoprolol</title>
          <description>Participants will receive intravenous metoprolol in between scans.</description>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.82</p_value>
            <p_value_desc>p value is 0.82 for 'Pre-Metoprolol' vs 'post-Metoprolol' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Ejection Fraction Pre and Post Metoprolol</title>
        <description>Participants will receive intravenous metoprolol in between scans.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction Pre and Post Metoprolol</title>
          <description>Participants will receive intravenous metoprolol in between scans.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.30</p_value>
            <p_value_desc>p value is 0.30 for 'Pre-Metoprolol' vs 'post-Metoprolol' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Stroke Volume Pre and Post Metoprolol</title>
        <description>Participants will receive intravenous metoprolol in between scans.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Stroke Volume Pre and Post Metoprolol</title>
          <description>Participants will receive intravenous metoprolol in between scans.</description>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.36</p_value>
            <p_value_desc>p value is 0.36 for 'Pre-Metoprolol' vs 'post-Metoprolol' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Systolic Volume Pre and Post Metoprolol</title>
        <description>Participants will receive intravenous metoprolol in between scans.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Systolic Volume Pre and Post Metoprolol</title>
          <description>Participants will receive intravenous metoprolol in between scans.</description>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.36</p_value>
            <p_value_desc>p value is 0.36 for 'Pre-Metoprolol' vs 'post-Metoprolol' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Diastolic Volume Pre and Post Metoprolol</title>
        <description>Participants will receive intravenous metoprolol in between scans.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Diastolic Volume Pre and Post Metoprolol</title>
          <description>Participants will receive intravenous metoprolol in between scans.</description>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Metoprolol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.65</p_value>
            <p_value_desc>P-Value is 0.65 for 'Pre-Metoprolol' vs 'post-Metoprolol' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Energetic Efficiency Pre and Post Sildenafil</title>
        <description>Kinetic energy (from 4D flow) normalized to ventricular volume (from MRI). Participants will be given sildenafil in between imaging scans.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Energetic Efficiency Pre and Post Sildenafil</title>
          <description>Kinetic energy (from 4D flow) normalized to ventricular volume (from MRI). Participants will be given sildenafil in between imaging scans.</description>
          <units>µJ/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.25</p_value>
            <p_value_desc>P-Value is 0.25 for 'Pre-Sildenafil' vs 'Post-Sildenafil' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Right Ventricular Ejection Fraction Pre and Post Sildenafil</title>
        <description>Participants will be given sildenafil in between imaging scans. The term &quot;ejection fraction&quot; refers to the percentage of blood that's pumped out of a filled ventricle with each heartbeat.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricular Ejection Fraction Pre and Post Sildenafil</title>
          <description>Participants will be given sildenafil in between imaging scans. The term &quot;ejection fraction&quot; refers to the percentage of blood that's pumped out of a filled ventricle with each heartbeat.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.43</p_value>
            <p_value_desc>P-Value is 0.43 for 'Pre-Sildenafil' vs 'Post-Sildenafil' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Right Ventricular Stroke Volume Pre and Post Sildenafil</title>
        <description>Participants will be given sildenafil in between imaging scans.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricular Stroke Volume Pre and Post Sildenafil</title>
          <description>Participants will be given sildenafil in between imaging scans.</description>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.66</p_value>
            <p_value_desc>P-Value is 0.66 for 'Pre-Sildenafil' vs 'Post-Sildenafil' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Right Ventricular Systolic Volume Pre and Post Sildenafil</title>
        <description>Participants will be given sildenafil in between imaging scans.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricular Systolic Volume Pre and Post Sildenafil</title>
          <description>Participants will be given sildenafil in between imaging scans.</description>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.13</p_value>
            <p_value_desc>P-Value is 0.13 for 'Pre-Sildenafil' vs 'Post-Sildenafil' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Right Ventricular Diastolic Volume Pre and Post Sildenafil</title>
        <description>Participants will be given sildenafil in between imaging scans.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricular Diastolic Volume Pre and Post Sildenafil</title>
          <description>Participants will be given sildenafil in between imaging scans.</description>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.57</p_value>
            <p_value_desc>P-Value is 0.57 for 'Pre-Sildenafil' vs 'Post-Sildenafil' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Ejection Fraction Pre and Post Sildenafil</title>
        <description>Participants will be given sildenafil in between imaging scans.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction Pre and Post Sildenafil</title>
          <description>Participants will be given sildenafil in between imaging scans.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.25</p_value>
            <p_value_desc>P-Value is 0.25 for 'Pre-Sildenafil' vs 'Post-Sildenafil' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Stroke Volume Pre and Post Sildenafil</title>
        <description>Participants will be given sildenafil in between imaging scans.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Stroke Volume Pre and Post Sildenafil</title>
          <description>Participants will be given sildenafil in between imaging scans.</description>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.07</p_value>
            <p_value_desc>P-Value is 0.07 for 'Pre-Sildenafil' vs 'Post-Sildenafil' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Systolic Volume Pre and Post Sildenafil</title>
        <description>Participants will be given sildenafil in between imaging scans.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Systolic Volume Pre and Post Sildenafil</title>
          <description>Participants will be given sildenafil in between imaging scans.</description>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.36</p_value>
            <p_value_desc>P-Value is 0.36 for 'Pre-Sildenafil' vs 'Post-Sildenafil' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Diastolic Volume Pre and Post Sildenafil</title>
        <description>Participants will be given sildenafil in between imaging scans.</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Adults Born Premature</title>
            <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Diastolic Volume Pre and Post Sildenafil</title>
          <description>Participants will be given sildenafil in between imaging scans.</description>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.2" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Sildenafil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive statistics</non_inferiority_desc>
            <p_value>0.91</p_value>
            <p_value_desc>P-Value is 0.91 for 'Pre-Sildenafil' vs 'Post-Sildenafil' subgroup</p_value_desc>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sildenafil Followed by Metoprolol</title>
          <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.&#xD;
Pulmonary Function Testing: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.&#xD;
Electrocardiogram: Subjects will undergo an electrocardiogram to ensure sinus rhythm&#xD;
Cardiac Magnetic Resonance Imaging: Subjects will undergo positron magnetic resonance imaging to detect images of the heart&#xD;
Metoprolol: Subjects will receive intravenous metoprolol&#xD;
Sildenafil: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)</description>
        </group>
        <group group_id="E2">
          <title>Metoprolol Followed by Sildenafil</title>
          <description>Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given metoprolol in between imaging scans at one visit, and will receive intravenous sildenafil in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kara Goss</name_or_title>
      <organization>UT Southwestern, Dallas, Texas</organization>
      <phone>214-648-6868</phone>
      <email>kara.goss@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

